Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May:187:114406.
doi: 10.1016/j.bcp.2021.114406. Epub 2021 Jan 4.

P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications

Affiliations
Review

P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications

Lucas T Woods et al. Biochem Pharmacol. 2021 May.

Abstract

Purinergic receptors for extracellular nucleotides and nucleosides contribute to a vast array of cellular and tissue functions, including cell proliferation, intracellular and transmembrane ion flux, immunomodulation and thrombosis. In mammals, the purinergic receptor system is composed of G protein-coupled P1 receptors A1, A2A, A2B and A3 for extracellular adenosine, P2X1-7 receptors that are ATP-gated ion channels and G protein-coupled P2Y1,2,4,6,11,12,13 and 14 receptors for extracellular ATP, ADP, UTP, UDP and/or UDP-glucose. Recent studies have implicated specific P2Y receptor subtypes in numerous oncogenic processes, including cancer tumorigenesis, metastasis and chemotherapeutic drug resistance, where G protein-mediated signaling cascades modulate intracellular ion concentrations and activate downstream protein kinases, Src family kinases as well as numerous mitogen-activated protein kinases. We are honored to contribute to this special issue dedicated to the founder of the field of purinergic signaling, Dr. Geoffrey Burnstock, by reviewing the diverse roles of P2Y receptors in the initiation, progression and metastasis of specific cancers with an emphasis on pharmacological and genetic strategies employed to delineate cell-specific and P2Y receptor subtype-specific responses that have been investigated using in vitro and in vivo cancer models. We further highlight bioinformatic and empirical evidence on P2Y receptor expression in human clinical specimens and cover clinical perspectives where P2Y receptor-targeting interventions may have therapeutic relevance to cancer treatment.

Keywords: Cancer; Extracellular nucleotides; Metastasis; P2Y receptors; Proliferation; Purinergic receptors.

PubMed Disclaimer

Conflict of interest statement

7. Conflict of Interest

None to declare

Figures

Figure 1.
Figure 1.. Extracellular purinome signal integration.
Cell-specific responses to extracellular nucelotides result from the combined activation of P2X ATP-gated ion channels, P2Y G protein-coupled nucleotide receptors and P1 G protein-coupled adenosine receptors. Through the action of ectonucleotide triphosphate diphosphohydrolases (ENTPDs) and the ecto-5’-nucleotidase CD73, extracellular ATP is broken down to generate nucleotide di- and monophosphates and adenosine to shift the purinergic response from ATP-activated P2X and P2Y receptors to UDP and ADP-activated P2Y receptors and eventually to P1 adenosine receptors. Adenosine is then recycled through cell-surface nucleoside transporters that terminate the extracellular signal. Cell- and tissue-specific expression of P2R, P1R, ENTPD, CD73 and nucleoside transporters make up the local extracellular purinome and intracellular integration of ion flux and G protein-mediated signaling cascades determines the overall cellular response. Figure created with BioRender.com.

Similar articles

Cited by

References

    1. Burnstock G, Campbell G, Satchell D, Smythe A, Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut, Br J Pharmacol 40(4) (1970) 668–88. - PMC - PubMed
    1. Burnstock G, Historical review: ATP as a neurotransmitter, Trends Pharmacol Sci 27(3) (2006) 166–76. - PubMed
    1. Burnstock G, Discovery of purinergic signalling, the initial resistance and current explosion of interest, Br J Pharmacol 167(2) (2012) 238–55. - PMC - PubMed
    1. Fountain SJ, Burnstock G, An evolutionary history of P2X receptors, Purinergic Signal 5(3) (2009) 269–72. - PMC - PubMed
    1. Ludlow MJ, Traynor D, Fisher PR, Ennion SJ, Purinergic-mediated Ca2+ influx in Dictyostelium discoideum, Cell Calcium 44(6) (2008) 567–79. - PMC - PubMed

Publication types

MeSH terms